Clinical trial of histidine-copper and diethyldithiocarbamate combination therapy for patients with Menkes disease

Clinical trial of histidine-copper and diethyldithiocarbamate combination therapy for patients with Menkes disease - Histidine-copper and diethyldithiocarbamate combination therapy for Menkes disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005259

Enrollment

Registered

2011-03-18

Start date

2011-03-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menkes disease

Interventions

give a dose of copper-histidine and diethyldithiocarbamate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with Menkes disease

Exclusion criteria

Exclusion criteria: a case who dosen't approve the clinical trial.

Design outcomes

Primary

Measure	Time frame
improvement of central nerves system disorder	—

Countries

Japan

Contacts

Public ContactHiroyuki Awano

Kobe University Graduate School of Medicine Pediatrics

awahiro@med.kobe-u.ac.jp078-382-6090

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026